• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

直接口服抗凝剂在非典型血栓相关病症中的应用。

Direct Oral Anticoagulant Use in Atypical Thrombosis-Related Conditions.

作者信息

Chang Clement, Hoyos Mario, Owusu Yaw, Elewa Hazem

机构信息

1 Purdue University, West Lafayette, IN, USA.

2 Qatar University, Doha, Qatar.

出版信息

Ann Pharmacother. 2018 Feb;52(2):185-197. doi: 10.1177/1060028017731850. Epub 2017 Sep 16.

DOI:10.1177/1060028017731850
PMID:28918657
Abstract

OBJECTIVE

To review the published literature for evidence of the efficacy and safety of direct oral anticoagulants (DOACs) when used in the management of atypical thrombosis-related conditions.

DATA SOURCES

A comprehensive MEDLINE database search (1948 to July 2017) and EMBASE search (1980 to July 2017) were conducted using the search terms direct oral anticoagulant in combination with acute coronary syndrome (ACS), antiphospholipid antibody syndrome (APLAS), and cancer-associated thrombosis (CAT).

STUDY SELECTION AND DATA EXTRACTION

The literature search was limited to studies that were conducted in humans and published in English. Clinical trials, observational studies, and case series were selected.

DATA SYNTHESIS

A total of 20 published studies were selected from the literature. Only 1 randomized controlled study showed a significant reduction in cardiovascular outcomes on DOAC use in ACS patients but at the expense of increased bleeding. For the use of DOACs in APLAS, the evidence from case series seems to suggest low incidence of thromboembolic events or recurrent thrombosis in low-risk patients. Finally, in cancer patients, DOACs were comparable to warfarin in preventing CAT in 8 studies of different designs. Major bleeding with DOACs was not significantly lower than in patients who received an enoxaparin/warfarin regimen.

CONCLUSIONS

Until more evidence from the ongoing clinical trials is available, DOACs may not be favorable add-on therapy in ACS patients receiving standard antiplatelet therapy but may be alternative to warfarin in preventing or treating thrombosis in low-risk APLAS patients as well as in cases of CAT in which patients have to be managed with warfarin.

摘要

目的

回顾已发表文献,以寻找直接口服抗凝剂(DOACs)用于治疗非典型血栓相关疾病时有效性和安全性的证据。

数据来源

使用搜索词“直接口服抗凝剂”与“急性冠脉综合征(ACS)”、“抗磷脂抗体综合征(APLAS)”及“癌症相关血栓形成(CAT)”相结合,对MEDLINE数据库(1948年至2017年7月)和EMBASE数据库(1980年至2017年7月)进行全面检索。

研究选择与数据提取

文献检索限于在人类中开展并以英文发表的研究。选取了临床试验、观察性研究及病例系列。

数据综合

从文献中总共选取了20项已发表研究。仅有1项随机对照研究显示,ACS患者使用DOACs可显著降低心血管事件,但代价是出血增加。对于DOACs在APLAS中的应用,病例系列证据似乎表明,低风险患者血栓栓塞事件或复发性血栓形成的发生率较低。最后,在癌症患者中,在8项不同设计的研究中,DOACs在预防CAT方面与华法林相当。DOACs导致的大出血并不显著低于接受依诺肝素/华法林治疗方案的患者。

结论

在获得正在进行的临床试验的更多证据之前,DOACs可能不是接受标准抗血小板治疗的ACS患者的理想附加治疗,但在预防或治疗低风险APLAS患者的血栓形成以及必须使用华法林治疗的CAT病例中,可能是华法林的替代药物。

相似文献

1
Direct Oral Anticoagulant Use in Atypical Thrombosis-Related Conditions.直接口服抗凝剂在非典型血栓相关病症中的应用。
Ann Pharmacother. 2018 Feb;52(2):185-197. doi: 10.1177/1060028017731850. Epub 2017 Sep 16.
2
Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis.直接口服抗凝剂治疗的抗磷脂综合征患者血栓形成风险增加。来自国际患者水平数据荟萃分析的结果。
Autoimmun Rev. 2018 Oct;17(10):1011-1021. doi: 10.1016/j.autrev.2018.04.009. Epub 2018 Aug 11.
3
Recurrent Thrombosis With Direct Oral Anticoagulants in Antiphospholipid Syndrome: A Systematic Literature Review and Meta-analysis.抗磷脂综合征中直接口服抗凝剂的复发性血栓形成:系统文献回顾和荟萃分析。
Clin Ther. 2019 Sep;41(9):1839-1862. doi: 10.1016/j.clinthera.2019.06.015. Epub 2019 Aug 10.
4
Direct oral anticoagulants versus warfarin in patients with antiphospholipid syndrome: A meta-analysis of randomized controlled trials.直接口服抗凝剂与华法林用于抗磷脂综合征患者的疗效比较:一项随机对照试验的荟萃分析
Lupus. 2022 Oct;31(11):1335-1343. doi: 10.1177/09612033221118463. Epub 2022 Aug 13.
5
Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature.直接口服抗凝药物在抗磷脂综合征中的应用:这些药物是否是华法林的有效且安全的替代药物?文献系统评价。
Curr Rheumatol Rep. 2016 Dec;18(12):74. doi: 10.1007/s11926-016-0623-7.
6
Direct oral anticoagulants in antiphospholipid syndrome: Meta-analysis of randomized controlled trials.抗磷脂综合征中直接口服抗凝剂:随机对照试验的荟萃分析。
Autoimmun Rev. 2021 Jan;20(1):102711. doi: 10.1016/j.autrev.2020.102711. Epub 2020 Nov 13.
7
Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants.不断发展的动脉和静脉血栓治疗方法:直接口服抗凝剂的作用。
Circ Res. 2016 Apr 29;118(9):1409-24. doi: 10.1161/CIRCRESAHA.116.306925.
8
Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.复发性静脉血栓栓塞和大出血的病死率与阿司匹林、华法林和直接口服抗凝剂用于二级预防相关。
Thromb Res. 2015 Feb;135(2):243-8. doi: 10.1016/j.thromres.2014.10.033. Epub 2014 Dec 2.
9
Thrombosis of atypical location: how to treat patients in the era of direct oral anticoagulants?非典型部位血栓形成:直接口服抗凝剂时代如何治疗患者?
Pol Arch Intern Med. 2018 Oct 31;128(10):604-608. doi: 10.20452/pamw.4333. Epub 2018 Sep 20.
10
Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome.直接口服抗凝剂与华法林在单抗体或双抗体阳性抗磷脂综合征患者中的比较。
J Thromb Thrombolysis. 2022 Jul;54(1):67-73. doi: 10.1007/s11239-021-02587-0. Epub 2021 Nov 24.

引用本文的文献

1
Genetic and Non-Genetic Factors Impact on INR Normalization in Preprocedural Warfarin Management.遗传和非遗传因素对术前华法林管理中INR正常化的影响。
Pharmgenomics Pers Med. 2021 Aug 28;14:1069-1080. doi: 10.2147/PGPM.S322743. eCollection 2021.